Biology of Blood and Marrow Transplantation
Volume 15, Issue 7 , Pages 812-816 , July 2009

Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma

  • Gaurav C. Parikh

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Ali Imran Amjad

      Affiliations

    • Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • Rima M. Saliba

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Syed M.A. Kazmi

      Affiliations

    • Department of Internal Medicine, University of Texas, Houston, Texas
    • ,
  • Ziad U. Khan

      Affiliations

    • Department of Internal Medicine, University of Texas, Houston, Texas
    • ,
  • Amit Lahoti

      Affiliations

    • Renal Section, Division of General Internal Medicine, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Chitra Hosing

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Floralyn Mendoza

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Suhail R. Qureshi

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Donna M. Weber

      Affiliations

    • Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Michael Wang

      Affiliations

    • Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Uday Popat

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Amin M. Alousi

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Richard E. Champlin

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Sergio A. Giralt

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Muzaffar H. Qazilbash

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Muzaffar H.Qazilbash, MD, Department of Stem Cell Transplantation and Cellular Therapy, UT-MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030.

Received 19 February 2009 ,Accepted 16 March 2009.

References 

  1. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53:207–212
  2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  3. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–451
  4. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65:175–181
  5. Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–1893
  6. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97
  7. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  8. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27–33
  9. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–829
  10. Bird JM, Fuge R, Sirohi B, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol. 2006;134:385–390
  11. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–607
  12. Donato ML, Feasel AM, Weber DM, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006;107:463–466
  13. Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–549
  14. Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823–828
  15. Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005;5:1306–1311
  16. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115–1123
  18. Schuh A, Dandridge J, Haydon P, Littlewood TJ. Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant. 1999;24:1141–1143
  19. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. Hematol J. 2000;1:28–36
  20. Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39:279–283
  21. Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008;14:1401–1407

 Financial disclosure: See Acknowledgments on page 816.

PII: S1083-8791(09)00157-8

doi: 10.1016/j.bbmt.2009.03.021

Biology of Blood and Marrow Transplantation
Volume 15, Issue 7 , Pages 812-816 , July 2009

Article Tools

* Image Usage & Resolution